Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 12:18:223-232.
doi: 10.2147/TCRM.S303052. eCollection 2022.

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus

Affiliations
Review

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus

Ronak G Gandhi et al. Ther Clin Risk Manag. .

Abstract

Purpose of review: Cytomegalovirus (CMV) infections are a common complication in solid organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased morbidity and mortality. Currently available treatment options have reduced the burden of infection, but utilization of these agents can be limited by toxicities such as nephrotoxicity and/or myelosuppression as well as emergence of resistance. The expansion of our current armamentarium towards CMV infection is crucial. Here, we review an emerging therapy, maribavir, and the safety and efficacy of this potential new agent for the prophylaxis and treatment of CMV infections including resistant/refractory disease.

Recent findings: Maribavir is a novel agent with CMV activity approved by Federal Food and Drug Administration (FDA) in December 2021 for resistant/refractory disease. Compared to currently available treatment for CMV infection, maribavir has a unique mechanism of action, retains activity against most (val)ganciclovir resistant strains, provides a more predictable pharmacokinetic profile, and fewer severe toxicities. Maribavir has been studied in phase 2 and 3 studies with ongoing phase 3 studies. While maribavir failed to meet the primary endpoints in the initial phase 3 study for prophylaxis therapy in allogeneic-HSCT and liver transplant recipients, results from the phase 2 study when used for pre-emptive therapy after HSCT show similar efficacy to valganciclovir, and results from the phase 3 study examining resistant/refractory disease demonstrate superiority to investigator-initiated therapy of (val)ganciclovir, foscarnet, or cidofovir.

Summary: Maribavir provides a new agent for the management of resistant/refractory CMV infection. Results of the recently published phase 3 study provide further insight into the role of this novel therapy.

Keywords: cytomegalovirus; efficacy; maribavir; safety.

PubMed Disclaimer

Conflict of interest statement

Ronak G. Gandhi has been a paid consultant to Takeda and Shionogi. Camille N. Kotton has been a paid consultant to Biotest, GSK, Merck, Takeda, Roche Diagnostics, and Hookipa. The authors report no other conflicts of interest in this work.

Similar articles

Cited by

References

    1. Kotton CN. CMV: prevention, Diagnosis and Therapy. Am J Transplant. 2013;13(Suppl 3):24–40; quiz 40. doi:10.1111/ajt.12006 - DOI - PubMed
    1. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931. doi:10.1097/TP.0000000000002191 - DOI - PubMed
    1. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017;64(1):87–91. doi:10.1093/cid/ciw668 - DOI - PubMed
    1. Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. N Engl J Med. 2019;381(12):1136–1147. doi:10.1056/NEJMoa1714656 - DOI - PubMed
    1. Chemaly RF, Chou S, Einsele H, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019;68(8):1420–1426. doi:10.1093/cid/ciy696 - DOI - PMC - PubMed